Negative Regulation of the Wnt-beta-catenin Pathway by the Transcriptional Repressor HBP1

Overview

Journal EMBO J

Specialties Biotechnology
Molecular Biology

Date 2001 Aug 14

PMID 11500377

Citations 70

Authors

E M Sampson

Z K Haque

M C Ku

S G Tevosian

C Albanese

R G Pestell

K E Paulson

A S Yee

Affiliations

Soon will be listed here.

Abstract

In certain cancers, constitutive Wnt signaling results from mutation in one or more pathway components. The result is the accumulation and nuclear localization of beta-catenin, which interacts with the lymphoid enhancer factor-1 (LEF)/T-cell factor (TCF) family of HMG-box transcription factors, which activate important growth regulatory genes, including cyclin D1 and c-myc. As exemplified by APC and axin, the negative regulation of beta-catenin is important for tumor suppression. Another potential mode of negative regulation is transcriptional repression of cyclin D1 and other Wnt target genes. In mammals, the transcriptional repressors in the Wnt pathway are not well defined. We have previously identified HBP1 as an HMG-box repressor and a cell cycle inhibitor. Here, we show that HBP1 is a repressor of the cyclin D1 gene and inhibits the Wnt signaling pathway. The inhibition of Wnt signaling and growth requires a common domain of HBP1. The apparent mechanism is an inhibition of TCF/LEF DNA binding through a physical interaction with HBP1. These data suggest that the suppression of Wnt signaling by HBP1 may be a mechanism to prevent inappropriate proliferation.

Citing Articles

Life in the fastlane? A comparative analysis of gene expression profiles across annual, semi-annual, and non-annual killifishes (Cyprinodontiformes: Nothobranchiidae).

Leow C, Piller K PLoS One. 2024; 19(9):e0308855.

PMID: 39255288 PMC: 11386455. DOI: 10.1371/journal.pone.0308855.

Transcriptome Profiling of the Hippocampal Seizure Network Implicates a Role for Wnt Signaling during Epileptogenesis in a Mouse Model of Temporal Lobe Epilepsy.

Mardones M, Gupta K Int J Mol Sci. 2022; 23(19).

PMID: 36233336 PMC: 9569502. DOI: 10.3390/ijms231912030.

Countering Triple Negative Breast Cancer via Impeding Wnt/β-Catenin Signaling, a Phytotherapeutic Approach.

Arzi L, Mollaei H, Hoshyar R Plants (Basel). 2022; 11(17).

PMID: 36079579 PMC: 9460573. DOI: 10.3390/plants11172191.

Cooperative defenses during enteropathogenic infection.

Troha K, Ayres J Curr Opin Microbiol. 2021; 65:123-130.

PMID: 34847524 PMC: 8818259. DOI: 10.1016/j.mib.2021.11.003.

CRISPR interference and activation of the microRNA-3662-HBP1 axis control progression of triple-negative breast cancer.

Yi B, Wang S, Wang X, Liu Z, Zhang C, Li M Oncogene. 2021; 41(2):268-279.

PMID: 34728806 PMC: 8781987. DOI: 10.1038/s41388-021-02089-6.

References

Zorn A, Barish G, Williams B, Lavender P, Klymkowsky M, Varmus H . Regulation of Wnt signaling by Sox proteins: XSox17 alpha/beta and XSox3 physically interact with beta-catenin. Mol Cell. 1999; 4(4):487-98. DOI: 10.1016/s1097-2765(00)80200-2. View

Shtutman M, Zhurinsky J, Simcha I, Albanese C, DAmico M, Pestell R . The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A. 1999; 96(10):5522-7. PMC: 21892. DOI: 10.1073/pnas.96.10.5522. View

Zhuma T, Tyrrell R, Sekkali B, Skavdis G, Saveliev A, Tolaini M . Human HMG box transcription factor HBP1: a role in hCD2 LCR function. EMBO J. 1999; 18(22):6396-406. PMC: 1171702. DOI: 10.1093/emboj/18.22.6396. View

Morin P . beta-catenin signaling and cancer. Bioessays. 1999; 21(12):1021-30. DOI: 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P. View

Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T . AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet. 2000; 24(3):245-50. DOI: 10.1038/73448. View

Li Y, Hively W, Varmus H . Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene. 2000; 19(8):1002-9. DOI: 10.1038/sj.onc.1203273. View

Lin S, Xia W, Wang J, Kwong K, Spohn B, Wen Y . Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A. 2000; 97(8):4262-6. PMC: 18221. DOI: 10.1073/pnas.060025397. View

Chen R, Ding W, McCormick F . Wnt signaling to beta-catenin involves two interactive components. Glycogen synthase kinase-3beta inhibition and activation of protein kinase C. J Biol Chem. 2000; 275(23):17894-9. DOI: 10.1074/jbc.M905336199. View

Polakis P . Wnt signaling and cancer. Genes Dev. 2000; 14(15):1837-51. View

10.

Lemercier C, Duncliffe K, Boibessot I, Zhang H, Verdel A, Angelov D . Involvement of retinoblastoma protein and HBP1 in histone H1(0) gene expression. Mol Cell Biol. 2000; 20(18):6627-37. PMC: 86159. DOI: 10.1128/MCB.20.18.6627-6637.2000. View

11.

Billin A, Thirlwell H, Ayer D . Beta-catenin-histone deacetylase interactions regulate the transition of LEF1 from a transcriptional repressor to an activator. Mol Cell Biol. 2000; 20(18):6882-90. PMC: 88764. DOI: 10.1128/MCB.20.18.6882-6890.2000. View

12.

Bienz M, Clevers H . Linking colorectal cancer to Wnt signaling. Cell. 2000; 103(2):311-20. DOI: 10.1016/s0092-8674(00)00122-7. View

13.

Hovanes K, Li T, Munguia J, Truong T, Milovanovic T, Marsh J . Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet. 2001; 28(1):53-7. DOI: 10.1038/ng0501-53. View

14.

Lin K, Zhao W, Bhatnagar J, Zhao W, Lu J, Simko S . Cloning and expression of human HBP1, a high mobility group protein that enhances myeloperoxidase (MPO) promoter activity. Leukemia. 2001; 15(4):601-12. DOI: 10.1038/sj.leu.2402071. View

15.

Shih H, Xiu M, Berasi S, Sampson E, Leiter A, Paulson K . HMG box transcriptional repressor HBP1 maintains a proliferation barrier in differentiated liver tissue. Mol Cell Biol. 2001; 21(17):5723-32. PMC: 87292. DOI: 10.1128/MCB.21.17.5723-5732.2001. View

16.

Tsukamoto A, Grosschedl R, Guzman R, Parslow T, Varmus H . Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell. 1988; 55(4):619-25. DOI: 10.1016/0092-8674(88)90220-6. View

17.

Zenklusen J, Bieche I, Lidereau R, Conti C . (C-A)n microsatellite repeat D7S522 is the most commonly deleted region in human primary breast cancer. Proc Natl Acad Sci U S A. 1994; 91(25):12155-8. PMC: 45395. DOI: 10.1073/pnas.91.25.12155. View

18.

Verbeek S, Izon D, Hofhuis F, Te Riele H, van de Wetering M, Oosterwegel M . An HMG-box-containing T-cell factor required for thymocyte differentiation. Nature. 1995; 374(6517):70-4. DOI: 10.1038/374070a0. View

19.

Zenklusen J, Thompson J, Klein-Szanto A, Conti C . Frequent loss of heterozygosity in human primary squamous cell and colon carcinomas at 7q31.1: evidence for a broad range tumor suppressor gene. Cancer Res. 1995; 55(6):1347-50. View

20.

Zenklusen J, Weitzel J, Ball H, Conti C . Allelic loss at 7q31.1 in human primary ovarian carcinomas suggests the existence of a tumor suppressor gene. Oncogene. 1995; 11(2):359-63. View